The discovery that a number of aberrant tumorigenic processes and signal transduction
pathways are mediated by druggable protein kinases has led to a revolutionary change in …

Although the proportion of patients with squamous cell carcinoma of the lung has declined
over the last two decades, the disease is still fatal for tens of thousands of patients each …

The past 30 years have seen the introduction of a number of cancer therapies with the aim of
restricting the growth and spread of primary and metastatic tumours. A shared commonality …

Lung cancer is the most common cancer type worldwide and the leading cause of cancer
related deaths in the United States. The majority of newly diagnosed patients present with …

Background We have previously characterized 19 ependymal tumors using Giemsa banding
and high-resolution comparative genomic hybridization. The aim of this study was to analyze …

Most patients with non–small-cell lung cancer (NSCLC) are elderly, and age has important
implications for their management and treatment. In May 2014, the Italian Association of …

Background: Crizotinib, an oral tyrosine kinase inhibitor that targets anaplastic lymphoma
kinase, has proven to offer sustained progression-free survival in anaplastic lymphoma …

This report describes a patient with ALK-rearranged non-small cell lung cancer who
developed diffuse leptomeningeal carcinomatosis as the only “site” of progression after a …

The anaplastic lymphoma kinase (ALK) is chromosomally rearranged in a subset of certain
cancers, including 2% to 7% of non–small cell lung cancers (NSCLC) and∼ 70% of …

Anaplastic lymphoma kinase (ALK) is correlated with oncogenesis in different types of
cancers, such as anaplastic large cell lymphoma, lung cancer, neuroblastoma, and even …